<?xml version='1.0' encoding='utf-8'?>
<document id="27666601"><sentence text="Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib - Enhancement by ketoconazole."><entity charOffset="92-104" id="DDI-PubMed.27666601.s1.e0" text="ketoconazole" /></sentence><sentence text="Icotinib (ICO), a novel small molecule and a tyrosine kinase inhibitor, was developed and approved recently in China for non-small cell lung cancer"><entity charOffset="0-8" id="DDI-PubMed.27666601.s2.e0" text="Icotinib" /><entity charOffset="10-13" id="DDI-PubMed.27666601.s2.e1" text="ICO" /><entity charOffset="45-53" id="DDI-PubMed.27666601.s2.e2" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.27666601.s2.e0" e2="DDI-PubMed.27666601.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27666601.s2.e0" e2="DDI-PubMed.27666601.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27666601.s2.e0" e2="DDI-PubMed.27666601.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27666601.s2.e1" e2="DDI-PubMed.27666601.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27666601.s2.e1" e2="DDI-PubMed.27666601.s2.e2" /></sentence><sentence text=" During screening for CYP inhibition potential in human liver microsomes (HLM), heterotropic activation toward CYP3A5 was revealed" /><sentence text=" Activation by icotinib was observed with CYP3A-mediated midazolam hydroxylase activity in HLM (∼40% over the baseline) or recombinant human CYP3A5 (rhCYP3A5) (∼70% over the baseline), but not in the other major CYPs including rhCYP3A4"><entity charOffset="15-23" id="DDI-PubMed.27666601.s4.e0" text="icotinib" /></sentence><sentence text=" When co-incubated with selective CYP3A4 inhibitor CYP3cide or monoclonal human CYP3A4 inhibitory antibody in HLM, the activation was extended to ∼60%, suggesting CYP3A5 might be the isozyme involved" /><sentence text=" Further, the relative activation was enhanced to ∼270% in rhCYP3A5 in the presence of ketoconazole"><entity charOffset="87-99" id="DDI-PubMed.27666601.s6.e0" text="ketoconazole" /></sentence><sentence text=" The activation was substrate and pathway dependent and observed only in the formation of 1'-OH-midazolam, and not 4-OH-midazolam, 6β-OH-testosterone, or oxidized nifedipine"><entity charOffset="90-105" id="DDI-PubMed.27666601.s7.e0" text="1'-OH-midazolam" /><entity charOffset="115-129" id="DDI-PubMed.27666601.s7.e1" text="4-OH-midazolam" /><entity charOffset="131-149" id="DDI-PubMed.27666601.s7.e2" text="6β-OH-testosterone" /><entity charOffset="163-173" id="DDI-PubMed.27666601.s7.e3" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.27666601.s7.e0" e2="DDI-PubMed.27666601.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27666601.s7.e0" e2="DDI-PubMed.27666601.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27666601.s7.e0" e2="DDI-PubMed.27666601.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27666601.s7.e0" e2="DDI-PubMed.27666601.s7.e3" /><pair ddi="false" e1="DDI-PubMed.27666601.s7.e1" e2="DDI-PubMed.27666601.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27666601.s7.e1" e2="DDI-PubMed.27666601.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27666601.s7.e1" e2="DDI-PubMed.27666601.s7.e3" /><pair ddi="false" e1="DDI-PubMed.27666601.s7.e2" e2="DDI-PubMed.27666601.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27666601.s7.e2" e2="DDI-PubMed.27666601.s7.e3" /></sentence><sentence text=" The activation requires the presence of cytochrome b5 and it is only observed in the liver microsomes of dogs, monkeys, and humans, but not in rats and mice" /><sentence text=" Kinetic analyses of 1'-OH-midazolam formation showed that ICO increased the Vmax values in HLM and rhCYP3A5 with no significant changes in Km values"><entity charOffset="21-36" id="DDI-PubMed.27666601.s9.e0" text="1'-OH-midazolam" /><entity charOffset="59-73" id="DDI-PubMed.27666601.s9.e1" text="ICO" /><pair ddi="false" e1="DDI-PubMed.27666601.s9.e0" e2="DDI-PubMed.27666601.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27666601.s9.e0" e2="DDI-PubMed.27666601.s9.e1" /></sentence><sentence text=" By adding CYP3cide with ICO to the incubation, the Vmax values increased 2-fold over the CYP3cide control"><entity charOffset="25-28" id="DDI-PubMed.27666601.s10.e0" text="ICO" /></sentence><sentence text=" Addition of ketoconazole with ICO alone or ICO plus CYP3cide resulted in an increase in Vmax values and decrease in Km values compared to their controls"><entity charOffset="13-25" id="DDI-PubMed.27666601.s11.e0" text="ketoconazole" /><entity charOffset="31-34" id="DDI-PubMed.27666601.s11.e1" text="ICO" /><entity charOffset="44-46" id="DDI-PubMed.27666601.s11.e2" text="ICO" /><pair ddi="false" e1="DDI-PubMed.27666601.s11.e0" e2="DDI-PubMed.27666601.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27666601.s11.e0" e2="DDI-PubMed.27666601.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27666601.s11.e0" e2="DDI-PubMed.27666601.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27666601.s11.e1" e2="DDI-PubMed.27666601.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27666601.s11.e1" e2="DDI-PubMed.27666601.s11.e2" /></sentence><sentence text=" This phenomenon may be attributed to a new mechanism of CYP3A5 heterotropic activation, which warrants further investigation" /><sentence text="" /></document>